Skip to main content
TNYA
NASDAQ Life Sciences

Tenaya Posts $18.9M Q3 Loss, Cash Through Q4 2027, Year-End Data on TN-201/TN-401

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$0.385
Mkt Cap
$84.311M
52W Low
$0.351
52W High
$1.56
52W Position info
9.7% above low
Off High info
75% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

TNYA is trading near its 52-week low of $0.351 (9.7% above the low).

Summary

Tenaya reported a $18.9M Q3 loss with $66.8M in cash funding operations into Q4 2027, and said pivotal-trial regulatory feedback plus longer-term TN-201 and TN-401 data are due by year-end.


Key Events · Earnings and Guidance · TNYA

  • Q3 Loss Narrows to $18.9M

    Net loss was $18.9M, or $0.08 per share, versus $20.3M ($0.12 per share) in Q3 2025; R&D fell to $14.9M from $15.4M and G&A held at $5.6M.

  • Cash Runway Into Q4 2027

    Cash and equivalents stood at $66.8M as of September 30, 2026, down from $100.5M at December 31, 2025, with management guiding to funding into Q4 2027.

  • Year-End Data and FDA Feedback Due

    One-year Cohort 2 and two-year Cohort 1 durability data for TN-201 and TN-401, plus regulatory feedback on pivotal trial planning, are all expected by year-end.

  • TN-301 Phase 2 Targeted for 2H 2027

    Study-enabling work is underway, with at least one company-sponsored Phase 2 trial in patients planned for the second half of 2027.


Analysis · TNYA · Life Sciences

The quarter itself is unremarkable — the loss narrowed to $18.9M from $20.3M and spending is flat — but the balance sheet is the story. With $66.8M in cash and a stated runway into Q4 2027, Tenaya has roughly a year of funding before it must raise again, and it is doing so at a $0.385 share price with a reverse split already queued for a December 9 shareholder vote. Everything now hinges on the year-end readouts: one-year Cohort 2 and two-year Cohort 1 durability data for both TN-201 and TN-401, plus regulatory feedback on pivotal trial designs. Those results determine whether the company can fund late-stage development or must dilute heavily first.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, TNYA was trading at $0.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $84.3M. The 52-week trading range was $0.35 to $1.56. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

TNYA - Latest Insights

TNYA
Nov 04, 2026, 4:41 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $0.377
Real-time Price: $0.2849 info
Change: -$0.0921 (-24%) info
Market Cap: $65.484M info
TNYA
Oct 13, 2026, 4:42 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Price at Filing: $0.530
Real-time Price: $0.2849 info
Change: -$0.2451 (-46%) info
Market Cap: $65.484M info
TNYA
Sep 14, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $0.6395
Real-time Price: $0.2849 info
Change: -$0.3546 (-55%) info
Market Cap: $65.484M info
TNYA
Aug 05, 2026, 4:46 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $0.7497
Real-time Price: $0.2849 info
Change: -$0.4648 (-62%) info
Market Cap: $65.484M info
TNYA
Jul 02, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.7865
Real-time Price: $0.2849 info
Change: -$0.5016 (-64%) info
Market Cap: $65.484M info